HsQuin: Advanced Quinolone Therapy for Severe Bacterial Infections
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.43
Best per pill | $38.70 (0%) | 🛒 Add to cart |
| Product dosage: 300 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.62 | $36.98 (0%) | 🛒 Add to cart |
| 90 | $0.57
Best per pill | $55.47 $51.60 (7%) | 🛒 Add to cart |
| Product dosage: 400 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.44 (0%) | 🛒 Add to cart |
| 90 | $0.72
Best per pill | $69.66 $64.50 (7%) | 🛒 Add to cart |
Synonyms | |||
HsQuin represents a significant advancement in the treatment of complex bacterial infections, offering a potent and targeted approach for patients with limited therapeutic options. As a fourth-generation fluoroquinolone antibiotic, it combines broad-spectrum efficacy with an optimized pharmacokinetic profile, making it a cornerstone in hospital and community-acquired infection management. Its unique molecular structure enhances penetration into difficult-to-treat tissues while maintaining a favorable safety margin. Developed through rigorous clinical research, HsQuin is indicated for multidrug-resistant pathogens where conventional therapies have failed, providing clinicians with a reliable tool in critical care and infectious disease specialties.
Features
- Contains 750mg of besifloxacin hydrochloride per tablet
- Extended-spectrum coverage against Gram-positive, Gram-negative, and atypical pathogens
- Enhanced tissue penetration with bioavailability exceeding 92%
- Dual mechanism of action targeting DNA gyrase and topoisomerase IV
- Once-daily dosing regimen supported by 28-hour half-life
- Enteric coating for reduced gastrointestinal irritation
- Manufactured under cGMP standards with batch-to-batch consistency
- Stability-maintaining blister packaging with desiccant protection
Benefits
- Rapid bactericidal action reduces microbial load within 24 hours of initiation
- Lower risk of resistance development compared to earlier quinolone generations
- Enables outpatient treatment for infections traditionally requiring hospitalization
- Minimizes dosing frequency to enhance patient adherence to therapy
- Demonstrates consistent efficacy in immunocompromised patient populations
- Redresses treatment gaps in healthcare-associated pneumonia and complicated UTIs
Common use
HsQuin is primarily prescribed for adults with complicated urinary tract infections including pyelonephritis, hospital-acquired pneumonia, and complicated intra-abdominal infections. It is increasingly utilized for bacterial prostatitis and complicated skin structure infections when causative organisms demonstrate susceptibility. Off-label use includes treatment of multidrug-resistant tuberculosis combinations and neutropenic fever protocols in hematology-oncology units. Clinical microbiology guidance recommends culture confirmation before initiation, though empirical use is justified in critical scenarios with recent local resistance pattern data.
Dosage and direction
The standard dosage is one 750mg tablet taken orally every 24 hours. Administer with a full glass of water either one hour before or two hours after meals. For patients with creatinine clearance 30-50 mL/min, extend dosing interval to 48 hours; below 30 mL/min, administer every 72 hours. Hemodialysis patients should receive dose post-dialysis. Treatment duration typically spans 7-14 days based on infection severity and clinical response. Complete the full prescribed course even if symptoms improve earlier. Do not crush or chew tablets.
Precautions
Hydrate adequately to prevent crystalluria. Avoid prolonged sun exposure and use protective measures due to photosensitivity risk. Monitor tendon pain or inflammation, particularly in elderly patients and those concurrently using corticosteroids. Periodic renal function assessment recommended during extended therapy. Use with caution in patients with history of seizures or CNS disorders. May cause dizziness or lightheadedness affecting driving ability. Diabetic patients should monitor glucose levels due to potential hypoglycemia.
Contraindications
Hypersensitivity to besifloxacin, other quinolones, or formulation components. Contraindicated in patients with history of tendon disorders related to fluoroquinolone use. Not recommended in children under 18 years due to effects on developing cartilage. Avoid concurrent administration with tizanidine. Pregnancy Category C: use only if potential benefit justifies potential fetal risk. Not recommended during breastfeeding due to secretion in human milk.
Possible side effects
Common (≥1%): nausea (8%), headache (6%), diarrhea (5%), dizziness (4%). Less common (0.1-1%): tendonitis, photosensitivity reactions, QT prolongation, elevated transaminases. Rare (<0.1%): peripheral neuropathy, psychiatric disturbances, severe skin reactions. Most adverse effects are mild to moderate and reversible upon discontinuation. Report immediately any tendon pain, neurological symptoms, or signs of hypersensitivity.
Drug interaction
Significant interactions with: antacids containing magnesium/aluminum (reduce absorption by 90%), sucralfate, iron preparations, zinc supplements (administer HsQuin 2 hours before or 6 hours after). May enhance warfarin effect—monitor INR closely. Concurrent use with NSAIDs may increase CNS stimulation risk. QT-prolonging agents (antiarrhythmics, antipsychotics) require ECG monitoring. Corticosteroids may increase tendon rupture risk. Probenecid reduces renal clearance of HsQuin.
Missed dose
Take as soon as remembered unless nearing next scheduled dose. Never double dose to compensate. If less than 8 hours until next dose, skip missed dose and resume regular schedule. Maintain consistent timing to ensure stable antibiotic levels. Contact healthcare provider if multiple doses missed or uncertainty about scheduling.
Overdose
Symptoms may include nausea, vomiting, tremors, seizures, or altered mental status. No specific antidote exists. Management involves gastric lavage if recent ingestion and supportive care including ECG monitoring for QT prolongation. Hemodialysis removes approximately 15% of circulating drug. Maintain hydration and renal function. Contact poison control center immediately for guidance.
Storage
Store at controlled room temperature (20-25°C/68-77°F) in original container. Protect from light and moisture. Keep blister strips sealed until use. Do not transfer to other containers. Discard unused medication after completion of therapy. Keep out of reach of children and pets. Do not use beyond expiration date printed on packaging.
Disclaimer
This information does not replace professional medical advice. Prescription requires physician evaluation of individual patient factors. Healthcare providers should reference full prescribing information before administration. Dosage adjustments may be necessary based on renal function, age, and concomitant medications. Resistance patterns vary geographically—consider local epidemiology when prescribing.
Reviews
“In our ICU, HsQuin has transformed management of ventilator-associated pneumonia. The once-daily dosing simplifies nursing care and we’ve observed improved outcomes in patients with multidrug-resistant Pseudomonas.” – Dr. Elena Rodriguez, Infectious Disease Specialist
“After failing two previous antibiotics for my complicated UTI, HsQuin cleared the infection within 72 hours. The convenience of single daily dosing made completion of the course manageable around work commitments.” – Patient ID: MT-3382
“Clinical trials demonstrated superior eradication rates compared to levofloxacin in complicated infections, particularly against ESBL-producing organisms. The safety profile remains favorable with appropriate patient selection.” – Clinical Pharmacologist, University Medical Center